Compare Abeona Therapeutics Inc (ABEO) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Tenet Healthcare Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Tenet Healthcare Corporation trades at $205.73 (market cap $17.76B). The key difference: Tenet Healthcare Corporation is far larger — about 47.6× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Tenet Healthcare Corporation nearer its low. Which is the better fit depends on your goals.
| ABEO | THC | |
|---|---|---|
Market Cap | $373.32M | $17.76B |
Sector | Health | Health |
52-Week High | $7.23 | $244.80 |
52-Week Low | $4.17 | $148.38 |
Enterprise Value | $228.22M | $28.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Tenet Healthcare (THC) trades at $206.19, up 1.21% today, with a bullish technical outlook supported by moving averages and strong analyst sentiment. The stock shows robust fundamentals with a P/E of 10.72, net income margin of 7.79%, and consistent earnings beats in recent quarters. Recent news highlights growth in outpatient care and positive market performance amid broader dips.
Outlook remains positive with an 81.25% analyst buy rating and $233.38 consensus price target, though overbought RSI signals near-term caution. Risks include healthcare regulatory pressures and debt levels, but expanding admissions and solid cash flow support long-term upside for value and growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
